David McSorley

2.3k total citations
33 papers, 1.8k citations indexed

About

David McSorley is a scholar working on Surgery, Gastroenterology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, David McSorley has authored 33 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Surgery, 14 papers in Gastroenterology and 9 papers in Pulmonary and Respiratory Medicine. Recurrent topics in David McSorley's work include Helicobacter pylori-related gastroenterology studies (13 papers), Gastrointestinal motility and disorders (10 papers) and Gastroesophageal reflux and treatments (4 papers). David McSorley is often cited by papers focused on Helicobacter pylori-related gastroenterology studies (13 papers), Gastrointestinal motility and disorders (10 papers) and Gastroesophageal reflux and treatments (4 papers). David McSorley collaborates with scholars based in United States, Netherlands and United Kingdom. David McSorley's co-authors include Allen W. Mangel, George E. Dukes, Allison R. Northcutt, Michael Camilleri, Emeran A. Mayer, Arthur A. Ciociola, Heath, Mayer, Kong and K. Turner and has published in prestigious journals such as The Lancet, Gastroenterology and Journal of Bone and Mineral Research.

In The Last Decade

David McSorley

31 papers receiving 1.7k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
David McSorley United States 14 1.4k 817 571 282 209 33 1.8k
Giuseppe Chiarioni Italy 29 2.1k 1.6× 2.0k 2.4× 283 0.5× 161 0.6× 213 1.0× 79 3.2k
Einar S. Björnsson Sweden 23 1.3k 1.0× 799 1.0× 467 0.8× 98 0.3× 195 0.9× 29 2.2k
W. Grant Thompson Canada 7 1.4k 1.1× 1.0k 1.3× 299 0.5× 148 0.5× 164 0.8× 13 2.0k
D G Maxton United Kingdom 18 700 0.5× 456 0.6× 287 0.5× 98 0.3× 106 0.5× 32 1.3k
Michael Camilleri United States 13 1.1k 0.8× 712 0.9× 334 0.6× 103 0.4× 79 0.4× 28 1.4k
Beatrice Salvioli Italy 20 1.0k 0.7× 724 0.9× 275 0.5× 73 0.3× 65 0.3× 45 1.4k
Yan Yiannakou United Kingdom 22 1.1k 0.8× 639 0.8× 229 0.4× 123 0.4× 99 0.5× 57 1.4k
Cesare Tosetti Italy 19 1.4k 1.0× 1.1k 1.4× 380 0.7× 112 0.4× 30 0.1× 44 1.8k
Philip Caenepeel Belgium 24 3.2k 2.3× 2.6k 3.2× 995 1.7× 221 0.8× 60 0.3× 71 4.4k
R.F. Harvey United Kingdom 15 731 0.5× 616 0.8× 284 0.5× 91 0.3× 75 0.4× 30 1.3k

Countries citing papers authored by David McSorley

Since Specialization
Citations

This map shows the geographic impact of David McSorley's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David McSorley with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David McSorley more than expected).

Fields of papers citing papers by David McSorley

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David McSorley. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David McSorley. The network helps show where David McSorley may publish in the future.

Co-authorship network of co-authors of David McSorley

This figure shows the co-authorship network connecting the top 25 collaborators of David McSorley. A scholar is included among the top collaborators of David McSorley based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David McSorley. David McSorley is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Hunter, Theresa, Carolyn Sweeney, Daniel Wolin, et al.. (2024). Evaluation of the Symptoms and Clinical Characteristics of Crohn’s Disease and Ulcerative Colitis That Affect Healthcare Providers’ Treatment Choices. Crohn s & Colitis 360. 6(4). otae053–otae053.
2.
Samuelson, Thomas W., Inder Paul Singh, Blake K. Williamson, et al.. (2021). Quality of Life in Primary Open-Angle Glaucoma and Cataract: An Analysis of VFQ-25 and OSDI From the iStent inject® Pivotal Trial. American Journal of Ophthalmology. 229. 220–229. 43 indexed citations
3.
Gilsenan, Alicia, et al.. (2020). Teriparatide Did Not Increase Adult Osteosarcoma Incidence in a 15-Year US Postmarketing Surveillance Study. Journal of Bone and Mineral Research. 36(2). 244–251. 55 indexed citations
4.
Oppenheimer, John, Beth Hahn, L. Zografos, et al.. (2020). Real-world evidence. Annals of Allergy Asthma & Immunology. 126(4). 385–393.e2. 14 indexed citations
5.
Samuelson, Thomas W., Inder Paul Singh, L. Jay Katz, et al.. (2019). PSS21 EFFECT OF ISTENT INJECT TRABECULAR MICRO-BYPASS ON PATIENT-REPORTED OUTCOMES FOR THOSE WITH OPEN-ANGLE GLAUCOMA AND COEXISTING CATARACTS. Value in Health. 22. S890–S890. 1 indexed citations
6.
7.
Davis, Kimberly H., Alex Asiimwe, L. Zografos, David McSorley, & Elizabeth Andrews. (2017). Evaluation of Risk-Minimization Activities for Cyproterone Acetate 2 mg/Ethinylestradiol 35 µg: A Cross-Sectional Physician Survey. Pharmaceutical Medicine. 31(5). 339–351. 12 indexed citations
8.
Chang, Lin, Vanessa Z. Ameen, George E. Dukes, et al.. (2005). A Dose-Ranging, Phase II Study of the Efficacy and Safety of Alosetron in Men with Diarrhea-Predominant IBS. The American Journal of Gastroenterology. 100(1). 115–123. 106 indexed citations
9.
Camilleri, Michael, William Y. Chey, Emeran A. Mayer, et al.. (2001). A Randomized Controlled Clinical Trial of the Serotonin Type 3 Receptor Antagonist Alosetron in Women With Diarrhea-Predominant Irritable Bowel Syndrome. Archives of Internal Medicine. 161(14). 1733–1733. 236 indexed citations
10.
Chey, William Y., et al.. (2001). Tolerability and safety of alosetron during long-term administration in female and male irritable bowel syndrome patients. The American Journal of Gastroenterology. 96(3). 803–811. 29 indexed citations
11.
Camilleri, Michael, et al.. (2000). Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial. The Lancet. 355(9209). 1035–1040. 448 indexed citations
12.
Hamm, Lynne, et al.. (1999). Urgency as an endpoint in IBS.. Gastroenterology. 116(4). 9 indexed citations
13.
Mangel, Allen W., et al.. (1999). Treatment of female IBS patients with alosetron, a potent and selective 5HT3-receptor antagonist. Gastroenterology. 116(4). 9 indexed citations
14.
15.
Ciociola, Arthur A., et al.. (1999). Helicobacter Pylori Infection Rates in Duodenal Ulcer Patients in The United States May Be Lower Than Previously Estimated. The American Journal of Gastroenterology. 94(7). 1834–1840. 166 indexed citations
16.
Lanza, Frank L., et al.. (1998). Ranitidine Bismuth Citrate Plus Clarithromycin: A Dual Therapy Regimen for Patients with Duodenal Ulcer. Helicobacter. 3(3). 212–221. 10 indexed citations
17.
Vakil, Nimish, et al.. (1998). Clarithromycin-Resistant Helicobacter pylori in Patients With Duodenal Ulcer in the United States. The American Journal of Gastroenterology. 93(9). 1432–1435. 100 indexed citations
18.
19.
Camilleri, Michael, D A Drossman, Lynne Hamm, et al.. (1998). Alosetron, a 5HT3-receptor antagonist, is effective in the treatment of female irritable bowel syndrome patients. Gastroenterology. 114. A812–A812. 18 indexed citations
20.
Moore, John G., et al.. (1995). Effects of Sucralfate and Ranitidine on Aluminum Concentrations in Elderly Volunteers. Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy. 15(6). 742–746. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Giuseppe Chiarioni Breakdown of academic impact, for papers by Einar S. Björnsson Breakdown of academic impact, for papers by W. Grant Thompson Breakdown of academic impact, for papers by D G Maxton Breakdown of academic impact, for papers by Michael Camilleri Breakdown of academic impact, for papers by Beatrice Salvioli Breakdown of academic impact, for papers by Yan Yiannakou Breakdown of academic impact, for papers by Cesare Tosetti Breakdown of academic impact, for papers by Philip Caenepeel Breakdown of academic impact, for papers by R.F. Harvey
Rankless by CCL
2026